TCGA-C8-A274-01A-11R-A16F-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 17
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.240
- PROTEIN_SECRETION+0.240
- ESTROGEN_RESPONSE_EARLY+0.210
- MITOTIC_SPINDLE+0.210
- G2M_CHECKPOINT+0.130
- UNFOLDED_PROTEIN_RESPONSE+0.100
- ESTROGEN_RESPONSE_LATE+0.090
- GLYCOLYSIS+0.080
- HEME_METABOLISM+0.080
- E2F_TARGETS+0.040
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- ALLOGRAFT_REJECTION-0.440
- TNFA_SIGNALING_VIA_NFKB-0.430
- ANGIOGENESIS-0.380
- WNT_BETA_CATENIN_SIGNALING-0.380
- INFLAMMATORY_RESPONSE-0.340
- HEDGEHOG_SIGNALING-0.330
- IL6_JAK_STAT3_SIGNALING-0.330
- INTERFERON_GAMMA_RESPONSE-0.320
- UV_RESPONSE_UP-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617882 | — | B | 0.865 |
| 2 | TCGA-AR-A0TR-01A-11R-A084-07 | — | B | 0.859 |
| 3 | fa14d20e-a75a-4572-b253-eb2fb8fa5504 | — | — | 0.856 |
| 4 | TCGA-E2-A15K-06A-11R-A12P-07 | — | B | 0.854 |
| 5 | 20050053.LumB | — | B | 0.843 |
| 6 | 20050151.LumB | — | B | 0.837 |
| 7 | SRR657325 | GTEX | — | 0.830 |
| 8 | TCGA-G2-A3VY-01A-11R-A22U-07 | — | — | 0.829 |
| 9 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.829 |
| 10 | TCGA-E9-A1N3-01A-12R-A157-07 | — | B | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.040 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |